Advertisement
U.S. Markets closed

Diagonal Bio AB (publ) (DIABIO.ST)

Stockholm - Stockholm Real Time Price. Currency in SEK
0.0351-0.0037 (-9.54%)
At close: 05:29PM CEST

Diagonal Bio AB (publ)

The Spark
Medicon Village ScheelevAegen 1
Lund 223 81
Sweden
46 7 03 05 24 88
https://diagonalbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 4

Key Executives

NameTitlePayExercisedYear Born
Ms. Karin Wehlin MBAChief Executive Officer64kN/A1963
Mr. Kushagr PunyaniTech Advisor, Founding Partner & Director100kN/A1991
Mr. Andreas NybergFounder & Chief Scientific OfficerN/AN/AN/A
Mr. Johan KallstrandFounding PartnerN/AN/AN/A
Ms. Fata MrsicChief Financial OfficerN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Diagonal Bio AB (publ) operates as a biotechnology company in Sweden. The company offers LAMPlify, a customized system for general laboratory use to identify the presence of specific genetic markers for, for example, fungi, viruses, or bacteria. It is also involved in the development of PANVIRAL, a universal in vitro diagnostic system, that offers the potential for rapid and accurate point-of-care diagnoses in various settings, such as doctor's office, surgery, mobile clinics, hospital bedsides, and workplaces and airports. The company was incorporated in 2020 and is based in Lund, Sweden.

Corporate Governance

Diagonal Bio AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.